Presence of human papillomaviruses and p16 expression in hypopharyngeal cancer

Head and Neck

Volumn 36, Issue 1, 2014, Pages 107-112

  Wendt, Malin ^a   Romanitan, Mircea ^a   Näsman, Anders ^a   Dalianis, Tina ^a   Hammarstedt, Lalle ^a   Marklund, Linda ^a   Ramqvist, Torbjörn ^a   Munck Wikland, Eva ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

head and neck cancer; human papillomavirus; hypopharynx; overall survival; p16

Indexed keywords

CARBOPLATIN; FLUOROURACIL; PROTEIN P16;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; HYPOPHARYNX CANCER; HYPOPHARYNX CARCINOMA; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; WART VIRUS;

HEAD AND NECK CANCER; HUMAN PAPILLOMAVIRUS; HYPOPHARYNX; OVERALL SURVIVAL; P16;

ADULT; AGED; ANALYSIS OF VARIANCE; COHORT STUDIES; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMAN PAPILLOMAVIRUS 16; HUMANS; HYPOPHARYNGEAL NEOPLASMS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84890441397     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23394     Document Type: Article

References (33)

1. Parkin DM, Bray F, Ferlay J, Pisani P,. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Cooper JS, Porter K, Mallin K, et al. National Cancer Database report on cancer of the head and neck: 10-year update. Head Neck 2009; 31: 748-758.
3. Hall SF, Groome PA, Irish J, O'Sullivan B,. The natural history of patients with squamous cell carcinoma of the hypopharynx. Laryngoscope 2008; 118: 1362-1371.
4. Takes RP, Strojan P, Silver CE, et al. Current trends in initial management of hypopharyngeal cancer: the declining use of open surgery. Head Neck 2012; 34: 270-281.
5. Guibert M, Lepage B, Woisard V, Rives M, Serrano E, Vergez S,. Quality of life in patients treated for advanced hypopharyngeal or laryngeal cancer. Eur Ann Otorhinolaryngol Head Neck Dis 2011; 128: 218-223.
6. WHO. IARC Monographs on the evaluation of carcinogenic risk to humans. Lyon, France: International Agency for Research on Cancer; 2007.
7. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008; 100: 261-269.
8. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010; 363: 24-35.
9. Attner P, Du J, Näsman A, et al. The role of human papillomavirus in the increased incidence of base of tongue cancer. Int J Cancer 2010; 126: 2879-2884.
10. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011; 29: 4294-4301.
11. Näsman A, Attner P, Hammarstedt L, et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer 2009; 125: 362-366.
12. Ramqvist T, Dalianis T,. Oropharyngeal cancer epidemic and human papillomavirus. Emerg Infect Dis 2010; 16: 1671-1677.
13. Romanitan M, Nasman A, Ramqvist T, et al. Human papillomavirus frequency in oral and oropharyngeal cancer in Greece. Anticancer Res 2008; 28: 2077-2080.
14. Ramqvist T, Dalianis T,. An epidemic of oropharyngeal squamous cell carcinoma (OSCC) due to human papillomavirus (HPV) infection and aspects of treatment and prevention. Anticancer Res 2011; 31: 1515-1519.
15. Deng Z, Hasegawa M, Matayoshi S, et al. Prevalence and clinical features of human papillomavirus in head and neck squamous cell carcinoma in Okinawa, southern Japan. Eur Arch Otorhinolaryngol 2011; 268: 1625-1631.
16. Klussmann JP, Gultekin E, Weissenborn SJ, et al. Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am J Pathol 2003; 162: 747-753.
17. El-Naggar AK, Westra WH,. p16 expression as a surrogate marker for HPV-related oropharyngeal carcinoma: a guide for interpretative relevance and consistency. Head Neck 2012; 34: 459-461.
18. Smeets SJ, Hesselink AT, Speel EJ, et al. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer 2007; 121: 2465-2472.
19. Mellin Dahlstrand H, Lindquist D, Bjornestal L, et al. P16(INK4a) correlates to human papillomavirus presence, response to radiotherapy and clinical outcome in tonsillar carcinoma. Anticancer Res 2005; 25: 4375-4383.
20. Hoffmann M, Tribius S, Quabius ES, et al. HPV DNA, E6(*)I-mRNA expression and p16(INK4A) immunohistochemistry in head and neck cancer-How valid is p16(INK4A) as surrogate marker? Cancer Lett 2012; 323: 88-96.
21. Klingenberg B, Hafkamp HC, Haesevoets A, et al. p16 INK4A overexpression is frequently detected in tumour-free tonsil tissue without association with HPV. Histopathology 2010; 56: 957-967.
22. Marur S, D'Souza G, Westra WH, Forastiere AA,. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 2010; 11: 781-789.
23. Hammarstedt L, Lindquist D, Dahlstrand H, et al. Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. Int J Cancer 2006; 119: 2620-2623.
24. Schmitt M, Bravo IG, Snijders PJ, Gissmann L, Pawlita M, Waterboer T,. Bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol 2006; 44: 504-512.
25. Ramqvist T, Du J, Lunden M, et al. Pre-vaccination prevalence of human papillomavirus types in the genital tract of 15-23-year-old women attending a youth health clinic in Stockholm, Sweden. Scand J Infect Dis 2011; 43: 115-121.
26. Marklund L, Näsman A, Ramqvist T, Dalianis T, Munck-Wikland E, Hammarstedt L,. Prevalence of human papillomavirus and survival in oropharyngeal cancer other than tonsil or base of tongue cancer. Cancer Med 2012; 1: 82-88.
27. Fischer M, von Winterfeld F,. Evaluation and application of a broad-spectrum polymerase chain reaction assay for human papillomaviruses in the screening of squamous cell tumours of the head and neck. Acta Otolaryngol 2003; 123: 752-758.
28. Hoffmann M, Gorogh T, Gottschlich S, et al. Human papillomaviruses in head and neck cancer: 8 year-survival-analysis of 73 patients. Cancer Lett 2005; 218: 199-206.
29. Sethi S, Ali-Fehmi R, Franceschi S, et al. Characteristics and survival of head and neck cancer by HPV status: a cancer registry-based study. Int J Cancer 2012; 131: 1179-1186.
30. Lewensohn-Fuchs I, Munck-Wikland E, Berke Z, et al. Involvement of aberrant p53 expression and human papillomavirus in carcinoma of the head, neck and esophagus. Anticancer Res 1994; 14: 1281-1285.
31. Ernoux-Neufcoeur P, Arafa M, Decaestecker C, et al. Combined analysis of HPV DNA, p16, p21 and p53 to predict prognosis in patients with stage IV hypopharyngeal carcinoma. J Cancer Res Clin Oncol 2011; 137: 173-181.
32. Doxtader EE, Katzenstein AL,. The relationship between p16 expression and high-risk human papillomavirus infection in squamous cell carcinomas from sites other than uterine cervix: a study of 137 cases. Hum Pathol 2012; 43: 327-332.
33. zur Hausen H,. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2: 342-350.